

Product Datasheet

Nesuparib

Catalog No. **BP-02155** · CAS **2055357-64-5** · Form **free base** · Physical state **other** · Color **White to off-white** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target PARP; Wnt; β-catenin	Research area Neurological Disease; Cancer
---------------------------------------	--

Molecular formula **C₂₃H₂₄N₆O**

Molecular weight **400.4763**

STRUCTURE



DESCRIPTION

Nesuparib (JPI-547) is the orally active inhibitor for PARP 1/2 and Tankyrase 1/2 that inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC₅₀s of 5, 1 and 2 nM, respectively. Nesuparib exhibits antitumor activity and can be used in research of advanced solid tumor.

BIOLOGICAL ACTIVITY

In Vitro

Nesuparib inhibits the activities of tankyrases, stabilizes AXIN protein, affects its downstream signaling pathways (WNT/β-catenin and Hippo signaling pathway), exhibiting antitumor effect.

In Vivo

Nesuparib exhibits antitumor activity against Olaparib (HY-10162)-resistant breast and ovary cancer in mouse BT474 or SNU251 xenograft models.

SOLUBILITY

Soluble in DMSO 60 mg/mL

REFERENCES

- [1]. Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same. Patent WO2016200101A2.
- [2]. Im S A , et al. A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.[J]. Journal of Clinical Oncology, 2021, 39(15_suppl):3113-3113.
- [3]. Oh K S, et al. JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction[J]. Cancer Research, 2023,

83(7_Supplement): 4496-4496.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.